Project Grant K25HL179402
- Federal Project Grant Award Summary Massachusetts General Hospital's Research Management Division received a $867,656 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on May 1, 2026, with a completion date of February 28, 2031. The award funds research to determine the effectiveness of guideline-directed medical therapies (GDMT) for heart failure with mildly reduced ejection fraction (HFmrEF)—a...
- Federal Grant Award Summary Massachusetts General Hospital's Research Management Division received a $1,519,316 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2029. The award funds development and clinical validation of mechanomicroscopy, an innovative endoscopic imaging platform designed to enable transbronchial assessment of pulmonary hypertension (PH)...
- Federal Project Grant Award Summary Award Details: Massachusetts General Hospital's Research Management Division received $194,080 in federal funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award was obligated on February 15, 2026, with an ultimate completion date of August 17, 2027. Products and Services: This Project Grant supports health services research utilizing mixed methods to optimize the...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $247,500 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025 through August 31, 2027. The award supports research to develop a non-invasive biomarker-based classifier model for early detection of pulmonary vascular dysfunction (PVD) in acute respiratory distress syndrome (ARDS) patients. ARDS patients with PVD...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $700,857 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) on September 10, 2025, to investigate the respiratory effects of truncal adiposity in acute hypoxemic respiratory failure (AHRF). The research will employ computed tomography (CT) imaging with artificial intelligence-based segmentation and registration analysis to quantify how excess abdominal fat...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $739,474 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on August 18, 2025, to investigate the anti-fibrotic roles of stress-induced tRNA-derived small RNAs (tDRs) in cardiac fibrosis. The research will be conducted through May 31, 2030, and focuses on characterizing the mechanisms by which ASP-GTC-3' tDR, a regulatory RNA fragment derived from transfer RNA,...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $247,500 under the Cardiovascular Diseases Research program (CFDA 93.837) to validate a positron emission tomography (PET) imaging probe targeting CD206-positive macrophages for idiopathic pulmonary fibrosis (IPF) diagnosis and monitoring. The project, which commenced August 15, 2025 and concludes July 31, 2027, aims to develop and validate a PET imaging agent that shares...
- Federal Grant Award Summary Massachusetts General Hospital's Research Management Division received a $249,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 1, 2026 through March 31, 2029. The project entitled "Whole Genome Sequence Interpretation for Lipids to Discover New Genes and Mechanisms for Coronary Artery Disease" focuses on advancing genetic diagnostic capabilities...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The General Hospital Corporation (Massachusetts General Hospital) a Project Grant of $1.67 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This award, with an ultimate completion date of March 31, 2030, funds the development of a patient-specific optical biomarker to predict disease progression and mortality risk in early idiopathic pulmonary fibrosis...
- Federal Project Grant Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received an $848,141 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, with a completion date of March 31, 2031. The award funds research to develop and validate cardiac magnetic resonance (CMR) imaging-based diagnostic criteria for coronary microvascular dysfunction (MVD)—a condition affecting up to...
Massachusetts General Hospital's Research Management Division received $186,840 in federal funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for a project titled "Advanced Analysis of High-Resolution Cardiac Diffusion Tensor Images." The award was obligated on July 3, 2026, with a completion date of June 30, 2031. The research deliverables focus on advancing diffusion tensor MRI (DTI) imaging techniques and analysis methodologies for the myocardium, specifically through development of an inner-volume focused acquisition approach centered on the intraventricular septum that reduces image artifacts and increases spatial resolution approximately tenfold compared to conventional methods. The core products include development and validation of DTI phenomapping—a novel voxel-level analysis approach that generates subject and population matrices of 10 DTI-derived parameters per voxel, analyzed using principal component analysis and hierarchical clustering techniques. The research aims to establish microstructural phenotypes of healthy myocardium and disease states such as aortic stenosis, addressing signal-to-noise constraints through specialized 64-channel cardiac coil technology. This work represents a paradigm shift from traditional segment-or-patient-level DTI analysis to granular, voxel-by-voxel quantification, enabling detailed characterization of myocardial microstructural organization in both healthy and pathological conditions.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $186.8k | 7/8/26 |